Meet Parkinson’s Europe vice-president Susanna Lindvall as she gets involved in #UniteForParkinsons 2018
Author: Almaz OhenePublished: 8 March 2018
Prep: Cook: Serves:
On International Women’s Day, Susanna Lindvall, vice president of the European Parkinson’s Disease Association (Parkinson’s Europe), shares her hopes for #UniteForParkinsons 2018 – and explains why more female-focused research into Parkinson’s is essential
Today is International Women’s Day and we’re also only a few weeks away from World Parkinson’s Day, which is when the #UniteForParkinsons campaign hopes to hit new heights. Tell us about the campaign and how Parkinson’s Europe is getting involved.
We have been working very hard for the past few months generating support and interest from all of our global network. Our aim is for Parkinson’s organisations and supporters around the world to be inspired to come together on a bigger scale than ever to show what Parkinson’s truly is.
At Parkinson’s Europe, we believe this will only actually happen if we start working together as an international community in a real and tangible way. That’s what World Parkinson’s Day is all about and that’s why we created the #UniteForParkinsons campaign with Parkinson’s UK last year.
So, can you tell us about your role at Parkinson’s Europe and describe your typical day as a board member?
I am very interested in research, so on a typical day I begin by answering email questions relating to Parkinson’s studies and research. I have telephone conference meetings with pharmaceutical companies and I’m in contact with Parkinson’s professionals throughout Europe. I also do some writing for the Swedish Parkinson’s magazine.
What changes to Parkinson’s diagnosis and treatment have you seen during your time working within the sector?
If we look at the diagnosis process, nowadays there are studies ongoing in biomarkers providing early diagnosis including imaging techniques, cerebral spinal fluid analysis and changes in the retina in the eyes.
In terms of treatment, I am very happy that clinicians recognise that a lot of younger people can have Parkinson’s. I am also glad that non-motor symptoms such as anxiety, depression and physical pain are also a recognised part of the disease.
We now have a wide range of drugs and treatments such as oral drugs, deep brain stimulation, medication patches and intestinal gels for continuous intestinal administration, and neurologists have begun to see the importance of exercise in slowing the progression of the disease.
What are your hopes for Parkinson’s treatments in the next few years? And in the long term?
I’d like more studies to be carried out that focus on gender in Parkinson’s disease and the differences regarding progression of the condition. The gender-specific approach is very important and it’s necessary to pay special attention to the predictors that cause poor health and poor quality of life. At present, we don’t have a general understanding of the differences.
In many Parkinson’s studies, there aren’t any women included in the data. I think we need many more women participating so that we can learn how the progression of the disease in women compares with that in men. We will then also learn how Parkinson’s medications affect women’s and men’s bodies differently.
What are you most excited about in terms of Parkinson’s developments: will we see a cure in your lifetime?
My hopes regarding treatments in the next five years are that we will find ways to detect the condition in its very early stages. At the same time, we need neuroprotective drugs. A combination of these two factors would be great.
(L–R) Susanna Lindvall, Sara Riggare and Eli Pollard at Parkinson’s Europe’s European Unity Walk, 2012
What is your personal connection to Parkinson’s disease?
My mother had Parkinson’s, and my father was a doctor who took care of my mother for several years. Then gradually I got more and more involved in her care and treatment. Another close family member who had Parkinson’s for several years suffered from hallucinations. He was living alone and did not dare to go into the bedroom to change clothes and go to bed in the evening, because he thought he was seeing people in there listening to him. This went on for a long time before we realised what was happening. When we finally found out, we took him to the neurologist to change his medication. Everything became much better for him after that.
Is there an experience you’ve had with Parkinson’s, either personally or professionally, that has given you hope?
Yes, for me research gives me hope. Because if you are looking at the exponential increase in the amount of research being carried out, all the ongoing studies and publications, for me it says that it has to result in a major breakthrough. When I see healthcare professionals and people with Parkinson’s share positive experiences and good models of care that improve quality of life – which is of vital importance – this also gives me hope.
What do you hope the campaign will achieve this year and in the future?
We really need the international Parkinson’s community – and by that I mean individuals, families, charities, healthcare professionals, decision makers and commercial companies from all over the world – supporting #UniteForParkinsons and getting involved. Last year it was a hashtag, this year it’s the hashtag and videos. Next year, who knows? What I do know is that from a Parkinson’s Europe perspective, we can’t make change happen on our own. But if we work together, then in theory anything is possible. And that’s what the #UniteForParkinsons campaign is all about.
Susanna has been the vice-president of the Parkinson’s Europe (Parkinson’s Europe) since 2005. She was born in Romania but has lived in Sweden since 1962, where she gained a BSc in organic chemistry from the University of Stockholm. From 1996 to 2002 she was president of ParkinsonFörbundet, the Swedish Parkinson’s Disease Association (SPA). She worked for many years as an information specialist at dairy company Arla Foods until her retirement in 2010.
Parkinson’s Europe and Parkinson’s UK are running the #UniteForParkinsons campaign to coincide with World Parkinson’s Day on 11 April. Get involved on the day by making your own Parkinson’s video and sharing it on social media using the hashtag. For more information, visit the website. Campaign toolkits are available to download in English, French, German, Italian, Spanish and Welsh. A Dutch version will also soon be available.
12 of the best domestic tools for people with Parkinson’s
A room-by-room roundup
6 days ago
Could a sea sponge support the search for Parkinson’s disease treatments?
How could a molecule in a sea sponge help treat Parkinson’s and similar conditions? Researchers at the University of California, Los Angeles (UCLA), in the US, recently explored this question. Their findings were published in the journal ‘Science’. The team examined a molecule known as lissodendoric acid A, which appears to counteract other molecules that damage DNA, proteins and whole cells – and was recently discovered in a sea sponge. The research team used an oft-neglected compound called a cyclic allene to control a step in the chain of chemical reactions, which enabled them to create a version of the molecule in a lab. Scientists believe that the ability to synthetically produce lissodendoric acid A will help them assess whether it can inform future therapies for conditions like Parkinson’s. UCLA’s Professor Neil Garg, the corresponding author of the study, said: “We hope others will also be able to use cyclic…
Study finds just six minutes of daily exercise might delay onset of Parkinson’s disease
Regular exercise is a common therapeutic strategy for people with Parkinson’s. Now, a study from New Zealand has suggested that daily physical activity might even delay the onset of this condition. Published in ‘The Physiological Society’, the study focused on a protein called brain-derived neurotrophic factor (BDNF) – which has previously been shown to boost cognitive performance. The researchers assessed the impact of fasting and physical activity on BDNF production in 12 people aged 18 to 56. The tests involved fasting and completing exercises of varying intensity, such as cycling for six minutes, as well as combinations of both fasting and physical activity. The results showed that brief, intense exercise was the best option for increasing the production of BDNF – with the protein increasing by a factor of four to five times compared to light exercise or fasting. Because BDNF can protect the brain from cognitive decline, the findings could…
Machine learning may help predict risk of freezing of gait in Parkinson’s disease
Difficulty taking steps forward, often referred to as the freezing of gait (FOG), is a common symptom experienced by people with Parkinson’s and one that can be difficult to predict. China-based researchers suggest that machine learning – artificial intelligence (AI) that uses algorithms to analyse data – could help predict the risk of freezing of gait developing in the early stages of the condition. Their study, published in ‘npj Parkinson’s Disease’, gave laboratory and clinical data to a machine learning model brain. This information was collected from 158 adults with untreated early-stage Parkinson’s and 73 healthy adults over a five-year period. They found that the risk of FOG could be predicted with an accuracy rate of up to 78%. The study authors suggested that machine learning methods “have the potential to help predict future FOG in patients with early Parkinson’s at an individual level”.